Asked by: Kirsten Oswald (Scottish National Party - East Renfrewshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the cost to the public purse was of Government investment into kidney disease research in 2022-23; and which public bodies provided this investment.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Over the period of 2022/23, the National Institute for Health and Care Research (NIHR) has invested more than £3.9 million in funding and support for kidney disease research. Research into kidney disease has included, but is not limited to, projects exploring the multimorbidity of kidney disease and other conditions, predicting the risk of kidney failure for patients with chronic kidney disease in the United Kingdom, and assessing new diagnostic techniques.
The NIHR welcomes funding applications for research into any aspect of human health, including kidney disease. Applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money, and scientific quality.
Asked by: Stephanie Peacock (Labour - Barnsley East)
Question to the Department for Transport:
To ask the Secretary of State for Transport, if his Department will make an assessment of the potential impact of the brightness of LED headlights on local communities.
Answered by Guy Opperman - Parliamentary Under-Secretary (Department for Transport)
All types of road vehicle headlamps are designed, tested and approved to internationally recognised standards to help prevent undue glare on a broad range of roads and environments. However, the Government is aware of concerns raised by members of the public and we intend to commission independent research shortly.
While there are clear safety, security and economic benefits associated with the use of LED lighting, the scientific evidence base on its adverse effects is less advanced. The government is committed to improving the evidence base to ensure we understand the effects more fully before making further policy interventions.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they will encourage the National Institute for Health and Care Research to rigorously evaluate existing research efforts and review how they can further prioritise and drive research investment for pancreatic cancer and other less survivable cancers.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in the fight against cancer, which is why the Department invests £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121 million for 2022/23.
In terms of establishing targeted funding into pancreatic cancer, the NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
The Government, through the NIHR, is committed to improving research into pancreatic cancer and cancers with the poorest survival rates by funding high quality, timely research that leads to improved outcomes for patients and the public, and makes the health and social care system more efficient, effective, and safe. Research evidence is vital for improving treatments and outcomes for people, including those with pancreatic cancer and other less survivable cancers.
In 2023, the Government awarded £2 million to new interdisciplinary research teams tackling hard to treat cancers, via the Medical Research Council, which hosted a two-day cancer sandpit strategic funding opportunity, focused on technological innovation for understanding cancers with the poorest survival rates.
The NIHR has funded seven research projects for pancreatic cancer for the period 2019 to 2023, with a total committed spend of approximately £3.6 million. The NIHR also supports the delivery of pancreatic cancer research funded by those in the charity and public sectors. For example, since 2019, the NIHR Clinical Research Network has supported over 70 pancreatic cancer-related studies.
The NIHR continues to encourage and welcome applications for research into any aspect of human health, including pancreatic cancer. All applications are assessed for funding by peer review committees. The level of research spend in a particular area is driven by factors including the quality of the proposals and their scientific potential. All applications for research into pancreatic cancer and other less survivable cancers made through open competition have been funded.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they will establish targeted funding to prioritise and drive research investment into pancreatic cancer and the other less survivable cancers.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in the fight against cancer, which is why the Department invests £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121 million for 2022/23.
In terms of establishing targeted funding into pancreatic cancer, the NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
The Government, through the NIHR, is committed to improving research into pancreatic cancer and cancers with the poorest survival rates by funding high quality, timely research that leads to improved outcomes for patients and the public, and makes the health and social care system more efficient, effective, and safe. Research evidence is vital for improving treatments and outcomes for people, including those with pancreatic cancer and other less survivable cancers.
In 2023, the Government awarded £2 million to new interdisciplinary research teams tackling hard to treat cancers, via the Medical Research Council, which hosted a two-day cancer sandpit strategic funding opportunity, focused on technological innovation for understanding cancers with the poorest survival rates.
The NIHR has funded seven research projects for pancreatic cancer for the period 2019 to 2023, with a total committed spend of approximately £3.6 million. The NIHR also supports the delivery of pancreatic cancer research funded by those in the charity and public sectors. For example, since 2019, the NIHR Clinical Research Network has supported over 70 pancreatic cancer-related studies.
The NIHR continues to encourage and welcome applications for research into any aspect of human health, including pancreatic cancer. All applications are assessed for funding by peer review committees. The level of research spend in a particular area is driven by factors including the quality of the proposals and their scientific potential. All applications for research into pancreatic cancer and other less survivable cancers made through open competition have been funded.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how much research funding the National Institute for Health and Care Research and the Medical Research Council have invested in biomedical studies of the causes and treatment of myalgic encephalomyelitis (ME) and non-biomedical studies of ME since 2019.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research through the National Institute for Health and Care Research (NIHR). Since 2019, the NIHR has awarded £1.9 million for research into myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome. The Medical Research Council (MRC), part of UK Research and Innovation (UKRI), has invested £3.6 million since 2019.
This funding includes the NIHR and UKRI co-funded DecodeME study, a £3.2 million study into the genetic underpinning of ME. The study will analyse samples from 25,000 people with ME, to search for genetic differences that may indicate underlying causes or an increased risk of developing the condition. This study aims to increase our understanding of the disease, and therefore contribute to the research base on diagnostic tests and targeted treatments for ME.
In 2020, the NIHR, the Chief Scientist Office in Scotland, and the MRC also funded the James Lind Alliance Priority Setting Partnership for ME, facilitated by the charity Action for ME. The report sets out the top 10 research priorities for ME. These recommendations have been co-produced through a process led by a steering group of people living with ME, carers, and clinicians.
In the interim delivery plan on ME, the Department recognised that there has been a relatively low amount of biomedical research funded on ME, compared with disease burden. The NIHR and MRC welcome applications for further biomedical research into ME. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all disease areas, the amount of funding depends on the volume and quality of scientific activity.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what progress they have made on the funding of biomedical research into myalgic encephalomyelitis (ME) since the then Parliamentary Under Secretary of State for Health and Social Care stated on 24 January 2019 that “there have not been good enough research proposals in the ME space, partly because of the stigma … and partly because of the division in the medical community”.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research through the National Institute for Health and Care Research (NIHR). Since 2019, the NIHR has awarded £1.9 million for research into myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome. The Medical Research Council (MRC), part of UK Research and Innovation (UKRI), has invested £3.6 million since 2019.
This funding includes the NIHR and UKRI co-funded DecodeME study, a £3.2 million study into the genetic underpinning of ME. The study will analyse samples from 25,000 people with ME, to search for genetic differences that may indicate underlying causes or an increased risk of developing the condition. This study aims to increase our understanding of the disease, and therefore contribute to the research base on diagnostic tests and targeted treatments for ME.
In 2020, the NIHR, the Chief Scientist Office in Scotland, and the MRC also funded the James Lind Alliance Priority Setting Partnership for ME, facilitated by the charity Action for ME. The report sets out the top 10 research priorities for ME. These recommendations have been co-produced through a process led by a steering group of people living with ME, carers, and clinicians.
In the interim delivery plan on ME, the Department recognised that there has been a relatively low amount of biomedical research funded on ME, compared with disease burden. The NIHR and MRC welcome applications for further biomedical research into ME. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all disease areas, the amount of funding depends on the volume and quality of scientific activity.
Asked by: Baroness Redfern (Conservative - Life peer)
Question to the Home Office:
To ask His Majesty's Government what plans they have (1) to review the standard duration of licences for animal research, and (2) to introduce more challenge into the system for granting such licences, given the pace of technological change in the sector.
Answered by Lord Sharpe of Epsom - Parliamentary Under-Secretary (Home Office)
The Home Office is going to conduct an internal review in relation to the duration of project licences for animal research under the Animals (Scientific Procedures) Act 1986 (ASPA), as announced in the parliamentary debate on 19 February 2024.
The use of animals in scientific procedures is only authorised by the Home Office Regulator where there is clear scientific benefit, to people, animals, or the environment. The regulatory framework has a rigorous approach to the application of the 3Rs (Replacement, Reduction and Refinement) in all applications for programmes of work involving animals. Establishments conducting research must have robust internal governance systems and processes that ensure the regulated activities carried out at the establishment are undertaken in accordance with the principles of the 3Rs. Our application of the 3Rs principles continuously evolves with scientific developments.
Asked by: Baroness Redfern (Conservative - Life peer)
Question to the Home Office:
To ask His Majesty's Government what plans they have (1) to increase the fees for licences to use animals in scientific research, and (2) to seek to reduce the use of animals in such research.
Answered by Lord Sharpe of Epsom - Parliamentary Under-Secretary (Home Office)
The Government has laid a Statutory Instrument in parliament to increase the fees payable for licences under the Animals (Scientific Procedures) Act 1986 (ASPA) to come into effect on 6th April 2024.
The Government recently announced that it will double investment, from £10m to £20m per annum, in research to achieve the three Rs (replacement, reduction and refinement) and develop non-animal alternatives. The Government will also publish a plan to accelerate the development, validation and uptake of technologies and methods to reduce reliance on the use of animals in science.
The Government is committed to opportunities for reducing the use of animals in scientific research. Specifically, this Government has recently accepted the recommendations of the independent Animals in Science Committee to further restrict the use of the forced swim test and apply enhanced scrutiny to any proposal to use it in research. However, we intend to go further and have set an aim to completely eliminate its use, thus driving the development and validation of suitable alternatives (see: www.gov.uk/government/publications/advice-on-the-use-of-the-forced-swim-test-letter-from-lord-sharpe/letter-from-lord-sharpe-of-epsom-responding-to-the-asc-forced-swim-test-report-accessible).
Asked by: Baroness Bennett of Manor Castle (Green Party - Life peer)
Question to the Department for Environment, Food and Rural Affairs:
To ask His Majesty's Government what assessment they have made of the findings of the SHOT-SWITCH research project, published in Conservation Evidence, about the voluntary transition from hunting with lead to non-lead ammunition in Great Britain; and what plans they have to ban the use of lead shot in hunting in England.
Answered by Lord Douglas-Miller - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
The use of lead shot in England and Wales is already prohibited in specific circumstances by existing legislation – including on all foreshores, and in or over specified sites of special scientific interest, predominantly wetlands.
The Health and Safety Executive (HSE) is currently preparing recommendations on further action to restrict the use of lead in ammunition. This work has included looking at information submitted to them with regard to possible options to control the use of lead ammunition. The previous SHOT-SWITCH study has been considered and is referenced in the background document of evidence (attached to this answer) which was put out with the public consultation last year.
HSE expects to issue its final restriction opinions later this year. The decision to apply any UK REACH restrictions as a further regulatory measure, or not to do so, will subsequently be made by the Defra Secretary of State, with the consent of the Scottish and Welsh Ministers.
Asked by: Charles Walker (Conservative - Broxbourne)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the level of NHS funding for brain tumour research compared to research into other cancers; and if she will provide the quantum of NHS research funding into brain tumours for each of the last five financial years.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department invests over £1 billion per year into health research, through the National Institute for Health Research (NIHR), whose research spending for all cancers was £121.8 million in 2022/23. Funding for the delivery of brain cancer studies in the National Health Service cannot be disaggregated from other studies, but to indicate scale, in 2022/23 the NIHR Clinical Research Network supported 61 brain cancer studies and recruited 4,317 participants to these studies.
Over the past five financial years, the NIHR has spent over £11.3 million in funding for brain cancer research. The following table shows the amount of funding awarded for brain cancer research, from 2018/19 to 2022/23:
Financial Year | Funding amount |
2018/19 | £2.9 million |
2019/20 | £150,000 |
2020/21 | £2.2 million |
2021/22 | £5.3 million |
2022/23 | £750,000 |
Total | £11.3 million |
Note: the amount of funding awarded will differ to actual spend in a given year, as total spending will include that of multi-year awards made in previous years.
The NIHR funds research in response to proposals received from scientists, rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
To increase the quality, diversity, and number of brain cancer research proposals, the NIHR is working with the Tessa Jowell Brain Cancer Mission and the research community, to develop research capacity in the brain cancer community.